Labcorp account plan
Global laboratory services leader
At a glance
Labcorp is a global laboratory services company with nearly 71,000 employees and FY2025 revenue of $13,951.7 million, performing more than 750 million tests.
Labcorp Holdings, headquartered in Burlington, North Carolina, provides diagnostic testing to physicians, hospitals, health systems, payers and consumers, and laboratory services to pharmaceutical, biotechnology and diagnostic companies. In 2025 it performed more than 750 million tests, served clients in approximately 100 countries and supported more than 85% of the new drugs and therapeutic products approved by the FDA. FY2025 revenue was $13,951.7 million (+7.2%), operating income $1,384.7 million and net earnings attributable to Labcorp $876.5 million (diluted EPS $10.46). North America accounted for 87% of revenue. It has nearly 71,000 employees and is led by Chairman and CEO Adam Schechter.
Business units
Diagnostics Laboratories (Dx)
$10,876.5 million FY2025 revenue, 78% of group revenueCore and specialty testing through a network of primary and specialty laboratories in the U.S. and Canada, more than 2,200 patient service centers and more than 7,000 in-office phlebotomists, sold to physicians, health systems, payers and consumers through Labcorp OnDemand. Q3 2026 revenue rose 6.5% to $2,948.9 million, with segment operating margin of 16.7%; esoteric testing reached 42% of diagnostic revenue.
Biopharma Laboratory Services (BLS)
$3,098.2 million FY2025 revenue, 22% of group revenueCentral Laboratory services for clinical trials in approximately 100 countries and Early Development research laboratories (bioanalytical, safety assessment, chemistry manufacturing services); 59% of BLS revenue comes from outside the U.S. Q3 2026 revenue rose 8.5% to $866.7 million with a margin of 18.3%, and the backlog was $8.92 billion.
Strategic priorities
- Lead in specialty testing
- Labcorp targets oncology, neurology, autoimmune diseases and women's health; specialty testing grows about three times faster than the broader diagnostics market. Recent launches include the FDA-cleared Elecsys pTau-217 Alzheimer's blood test and an FDA-approved companion diagnostic for advanced melanoma.
- Partner of choice for health systems and pharma
- Labcorp signed or completed 13 collaboration transactions with health systems and local or regional labs in 2025; deals must be accretive in the first year and return the cost of capital by year three.
- Personalized health solutions
- Labcorp OnDemand offers over 140 panels and tests, including the Marker by Labcorp Genetic Health Panel, and the MyLabcorp AI-powered app has been downloaded by millions of consumers.
- Advanced technology
- Investor Day named AI and robotics as a priority; technology work covers Test Finder, laboratory robotics, digital pathology and the next generation of Labcorp Global Trial Connect.
- Long-term financial outlook through 2029
- Compound annual revenue growth of 5% to 8%, adjusted EPS growth of 8.5% to 11.5% and adjusted operating margin expansion of 75 to 150 basis points by the end of 2029.
- LaunchPad savings
- The LaunchPad program is on track for $125 million of savings in 2026 and is being accelerated to offset PAMA reimbursement cuts.
Latest results
In Q3 2026 (quarter ended September 30, 2026) revenue rose 6.9% to $3,810.0 million, with organic growth of 5.5%. Adjusted operating income was $570.0 million (15.0% margin, +60 bp), adjusted EPS $4.78 (+14.5%) and free cash flow $412.2 million, while GAAP operating income rose 1.4% to $402.1 million as LaunchPad and acquisition-related corporate costs increased. BLS grew 9.6% organically with a TTM book-to-bill of 1.10. Labcorp raised its 2026 guidance to revenue of $14,779-$14,887 million (+5.9% to 6.7%) and adjusted EPS of $18.30-$18.70, keeping free cash flow at $1,240-$1,360 million.
Investments and deals
- BioReference Health assets
- Agreement of October 15, 2026 with OPKO Health to acquire select BioReference Health assets, including the 4Kscore prostate cancer test, for up to $872.0 million, expected to close mid-2027.
- Myriad Prenatal Health and Millennium Health
- Agreements in October 2026 to acquire Myriad Genetics' Prenatal Health business for approximately $210.0 million and drug testing laboratory Millennium Health for up to $375.0 million.
- 2026 acquisitions completed
- Nine-month 2026 acquisitions totalled $789.1 million, including Empire City Laboratories, Parkview Health outreach assets and MLM Medical Labs, which gives Labcorp a wholly owned central lab network across four continents.
- Capex and new facilities
- Capex is planned at nearly 4% of revenue in 2026, for core growth, facility expansion, LaunchPad and integration; a new Central Lab facility is under construction in Indianapolis.
- SYNLAB minority stake
- A 15% minority interest in SYNLAB was acquired for approximately $151.6 million, closed March 2025, as a step toward global reach.
Challenges and risks
- PAMA reimbursement cuts
- Rate decreases are frozen for 2026 but resume in 2027, capped at 15% per year for 2027 to 2029; Labcorp's base case assumes about $125 million of impact in 2027.
- Payer utilization controls
- Prior authorization, laboratory benefit management programs, narrow networks and claims edits weigh on molecular, genetic and toxicology testing; ACA exchange changes cost about 30 basis points of Dx volume in Q3 2026.
- Biopharma R&D dependence
- BLS revenue depends on pharma, biotech and medical device R&D spending; Early Development was restructured in 2025, with $105.5 million of charges.
- ERP rollout and technology risk
- A new risk factor covers extending a new ERP system across the company, which could disrupt supply chain, procurement and transaction processing; cybersecurity and AI risks are also named.
- Refinancing at higher rates
- Labcorp expects to refinance its $600.0 million 3.60% senior notes due September 2027 at higher interest rates.
What leadership says
“Labcorp has never been more relevant than it is today”
“We are disappointed by the recent announcement on the proposed fee schedule changes related to PAMA”
“Our confidence in this outlook is grounded in a proven record of delivering on our commitments and a disciplined value creation framework that converts growth into earnings, cash flow and shareholder returns”
“The market typically grows at 1%-2%, so we're growing substantially more than the overall market”
Where a supplier can help
- Acquisition integration
- With BioReference, Myriad Prenatal Health and Millennium Health pending after $789.1 million of 2026 deals, Labcorp needs integration support across labs, patient service centers, billing and IT.
- Automation and robotics
- AI and robotics are a stated priority and LaunchPad savings are being accelerated against PAMA cuts; lab automation, robotics and workflow vendors fit both.
- ERP and procurement transformation
- The company-wide ERP extension is a named risk; implementation partners, data migration and change-management services can reduce disruption.
- Revenue cycle and payer management
- Reimbursement pressure and utilization controls such as prior authorization create demand for revenue cycle, claims and payer analytics tools.
- Clinical trial technology and logistics
- BLS is growing with a new Indianapolis Central Lab facility and Global Trial Connect enhancements; trial logistics, kit supply and sponsor portal technology providers can support that growth.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Labcorp?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Labcorp Holdings Inc. Annual Report on Form 10-K for fiscal year 2025
- Labcorp is a global laboratory services company with nearly 71,000 employees serving clients in approximately 100 countries; in 2025 it performed more than 750 million tests and supported more than 85% of the new drugs and therapeutic products approved by the FDA.
- FY2025 revenue was $13,951.7 million, up 7.2% (organic 4.4%, acquisitions net of divestitures 2.5%, currency 0.4%); operating income rose 27.4% to $1,384.7 million and net earnings attributable to Labcorp were $876.5 million (diluted EPS $10.46).
- Two segments: Diagnostics Laboratories (Dx) generated $10,876.5 million (78% of revenue, nearly all in the U.S.); Biopharma Laboratory Services (BLS: Central Laboratory and Early Development) generated $3,098.2 million (22%), with 59% of BLS revenue from outside the U.S.
- Near-term strategy: be the partner of choice for health systems and local/regional laboratories (13 collaboration transactions signed or completed in 2025) and lead in specialty testing in oncology, women's health, autoimmune disease and neurology.
- Longer-term priorities: cell and gene therapy, consumer-centric capabilities (more than 100 tests on Labcorp OnDemand) and global reach including companion diagnostics (CDx); a 15% minority stake in SYNLAB (Europe) closed in March 2025.
- Capital deployment in 2025: $582.0 million of acquisitions, $450.0 million of buybacks, $240.7 million of dividends; capex $434.5 million (3.1% of revenue), expected to rise to about 4.0% of revenue for growth, facilities, the LaunchPad program and integration.
- Early Development was restructured in 2025: $105.5 million of the $127.2 million restructuring charges related to ED.
- Key risks: U.S. reimbursement pressure (PAMA rate cuts frozen for 2026 but resuming in 2027, capped at 15% per year for 2027-2029), payer utilization management, FDA regulation of LDTs, dependence of BLS on biopharma R&D spending, cybersecurity and AI, acquisition integration.
- Labcorp Holdings Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 revenue was $3,810.0 million, up 6.9% (organic 5.5%, acquisitions net of divestitures 1.5%, currency -0.1%); nine-month revenue $11,078.7 million, up 6.2%.
- Dx revenue $2,948.9 million (+6.5%), with requisition volume +4.8% (organic 3.1%) and price/mix +1.7%; Dx segment operating income $491.6 million, margin 16.7% (up about 40 bp).
- BLS revenue $866.7 million (+8.5%, organic 9.6%); segment operating income $159.0 million, margin 18.3% (up about 180 bp) on organic growth and efficiencies from the Early Development (ED) actions.
- Total operating income rose only 1.4% to $402.1 million as corporate costs rose $43.3 million to $153.9 million on LaunchPad and acquisition-related costs.
- Nine-month acquisitions totalled $789.1 million (Empire City Laboratories, Parkview Health outreach, MLM Medical Labs); after quarter end Labcorp agreed to buy BioReference Health lab assets (up to $872.0 million), Myriad Genetics' Prenatal Health business (approximately $210.0 million) and Millennium Health (up to $375.0 million).
- Financing: $750.0 million 2026 Term Loan used to redeem the 1.55% notes due 2026; buyback authorization raised by $1,000.0 million in July, $1,378.6 million remaining at September 30, 2026; the $600.0 million 3.60% notes due September 2027 are to be refinanced at higher rates.
- New risk flagged: extending a new ERP system across the company could disrupt supply chain, procurement and transactions.
- Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
- Q3 2026 revenue $3.81 billion (+6.9%; organic 5.5%), adjusted operating income $570.0 million (15.0% margin, +60 bp), diluted EPS $3.22, adjusted EPS $4.78 (+14.5%), free cash flow $412.2 million.
- Dx: revenue $2,948.9 million (+6.5%, organic 4.4%), adjusted operating margin 16.7%; BLS: revenue $866.7 million (+8.5%, organic 9.6%; Central Labs +11.5%, Early Development +0.4%), adjusted operating margin 18.3% (+180 bp).
- BLS backlog $8.92 billion (+3.9%), TTM net orders $3.59 billion, TTM book-to-bill 1.10; $2.82 billion expected to convert in the next twelve months.
- 2026 guidance raised: revenue $14,779-$14,887 million (+5.9% to 6.7%), Dx +5.5% to 6.2%, BLS +7.4% to 8.4%, adjusted EPS $18.30-$18.70; free cash flow kept at $1,240-$1,360 million.
- Four transactions announced or closed: MLM Medical Labs (central/specialty lab in the U.S., Germany and South Africa), select BioReference Health assets, Myriad Genetics' Prenatal Health business and Millennium Health.
- Specialty testing: FDA approval of PGDx elio tissue complete CDx for advanced melanoma, launch of the FDA-cleared Elecsys pTau-217 Alzheimer's blood test, hepatitis D reflex testing; Labcorp OnDemand now offers over 140 panels and tests.
- Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
- At its September 10, 2026 Investor Day, Labcorp set a long-term outlook through 2029: compound annual revenue growth of 5% to 8% and compound annual adjusted EPS growth of 8.5% to 11.5%.
- It also targets adjusted operating margin expansion of 75 to 150 basis points by the end of 2029 and free cash flow growth in line with adjusted earnings growth.
- Four strategic priorities: lead in specialty testing (oncology, neurology, autoimmune diseases, women's health); be a partner of choice for health systems and leading pharma; drive personalized health solutions; shape the future through advanced technology including AI and robotics.
- 2026 guidance reaffirmed: revenue $14,710-$14,827 million (+5.4% to 6.3%), adjusted EPS $18.10-$18.55, free cash flow $1,240-$1,360 million.
- CEO Adam Schechter: "Labcorp has never been more relevant than it is today"; CFO Julia Wang grounds the outlook in "a proven record of delivering on our commitments".
- Labcorp Holdings Q3 2026 Earnings Call Transcript
- CEO Adam Schechter and CFO Julia Wang reported Q3 2026 revenue of $3.8 billion (+7%), adjusted EPS of $4.78 (+14.5%) and free cash flow of $412 million, and raised 2026 guidance (revenue +5.9% to 6.7%, adjusted EPS $18.30-$18.70).
- PAMA: Labcorp is "disappointed" by the proposed CMS fee schedule; base case assumes about $125 million impact in 2027 (traditional Medicare/Medicaid), most of it in the first year; it still backs the RESULTS Act and reaffirmed its 2026-2029 outlook.
- Four levers to offset PAMA: underlying Dx momentum, BLS strength, accelerated LaunchPad (on track for $125 million savings in 2026), and business development.
- M&A: four deals in about a month (MLM Medical Labs, BioReference Health assets, Myriad Prenatal Health, Millennium Health); BioReference expected to add $260 million of revenue and about $0.15 of adjusted EPS in year one; Myriad about $160 million of revenue; Schechter expects PAMA to enlarge the pipeline as smaller labs struggle.
- BLS: organic growth 9.6%, Central Lab +11.3% organic, book-to-bill 1.13 (1.10 TTM), backlog $8.9 billion; demand from large pharma, oncology and rising cardiometabolic/GLP-1 trials; new lab under construction in Indianapolis.
- Specialty testing grows about three times faster than the diagnostics market; esoteric revenue rose to 42% of diagnostic revenue in Q3 2026 from about 38% in Q1 2024.
- ACA exchange changes cost about 30 bp of Dx volume in Q3; that population is under 4%-5% of diagnostic volume.
- Labcorp Holdings Q2 2026 Earnings Call Transcript
- Q2 2026: revenue $3.7 billion (+5.8%), adjusted operating margin 15.8% (+70 bp), adjusted EPS $4.99 (+14.9%), free cash flow $314 million; 2026 guidance raised to revenue growth 5.4%-6.3% and adjusted EPS $18.10-$18.55.
- Specialty areas (oncology, neurology, autoimmune, women's health) delivered double-digit revenue growth in H1 2026; oncology expected to grow two to three times faster than the overall market; Labcorp offers over 6,500 tests.
- Dx organic growth 3.6% (1.8% volume, 1.8% price/mix); Schechter says the lab market typically grows 1%-2%, so Labcorp grows substantially faster, helped by hospital and regional lab deals.
- BLS revenue $836 million (+6.5%); Central Lab, about 70% of BLS, grew 7.6% organically; Early Development actions largely complete; BLS margin +130 bp to 17%; book-to-bill 1.14.
- Consumer: Labcorp OnDemand growing double digits with just over 200 biomarkers; Marker by Labcorp genetics launch; MyLabcorp AI app downloaded by millions; Epic Aura collaboration puts 6,500-plus tests on the platform.
- Capital: $226 million acquisitions (Parkview Health outreach, Tribal Diagnostics), $354 million buybacks, $500 million notes retired; buyback authorization raised by $1 billion to $1.4 billion.
- M&A bar: accretive in year one, return cost of capital in two to three years; pipeline "very strong" as hospitals face ACA and possible PAMA pressure.
Questions about Labcorp
What does Labcorp do?
Labcorp runs diagnostic laboratories serving physicians, health systems, payers and consumers, and provides central laboratory and early development services to biopharma companies; it performed more than 750 million tests in 2025.
What is Labcorp's revenue?
FY2025 revenue was $13,951.7 million, up 7.2%. For 2026 Labcorp guides revenue of $14,779-$14,887 million.
How many employees does Labcorp have?
Labcorp has nearly 71,000 employees serving clients in approximately 100 countries.
What is Labcorp's strategy?
Four priorities: lead in specialty testing, be a partner of choice for health systems and pharma, drive personalized health solutions, and use advanced technology including AI and robotics.
Who leads Labcorp?
Adam Schechter is Chairman and CEO, and Julia Wang is Executive Vice President and CFO.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)